Report on the risk assessment of MT-45 in the framework of the Council Decision on new psychoactive substances
This publication presents the data and findings of the risk assessment on MT-45 (1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The Risk Assessment Report, which was submitted to the European Commission and the Council of the European Union on 6 October 2014, examined the health and social risks of the drug, information on international trafficking and the involvement of organised crime, and the potential implications of subjecting the drug to control measures. MT-45 is the tenth new psychoactive substance to... be risk assessed under the terms of Council Decision 2005/387/JHA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 8 October 2015, the Council decided that MT-45 should be subject to control measures across the Member States. This decision is the final stage of the three-step process — early warning, risk assessment and control of new psychoactive substances — established by Council Decision 2005/387/JHA. This legal framework allows the EU institutions and Member States to act on all new and potentially threatening narcotic and psychotropic drugs that appear on the European drug scene, with the EMCDDA and Europol, in collaboration with their respective networks, playing a central role in the early detection of such substances and the harms caused by their use — information that underpins risk assessment and, ultimately, decision-making.
- Corporate author(s): European Monitoring Centre for Drugs and Drug Addiction (EU body or agency) Themes: Public health, Social problems
- Subject: drug addiction, health control, health policy, health risk, narcotic, psychotropic substance, public health, scientific report, stimulant